A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Number: NCT02266745
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Number: NCT02420977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
Number: NCT02526368
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of California, San Francisco|American Cancer Society, Inc.|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression
Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
Number: NCT02809690
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Southern California|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Number: NCT03207867
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
Number: NCT03262103
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ashutosh Kumar Tewari|Oncovir, Inc.|Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
Number: NCT03344211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Number: NCT03388619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Number: NCT03392181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Northwestern University|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Cardiff Oncology
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC
Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Number: NCT03460977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression
Number: NCT03507608
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Number: NCT03556228
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): VM Oncology, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients
Number: NCT03569280
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kangpu Biopharmaceuticals, Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of HPN424 in Patients With Advanced Prostate Cancer
Number: NCT03577028
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Number: NCT03585114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emerson Lim|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer
Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |
MGC018 With or Without MGA012 in Advanced Solid Tumors
Number: NCT03729596
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03751436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Roswell Park Cancer Institute|AbbVie
Sponsor Trial Information
Trial Location(s) and Contact(s) |
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
Number: NCT03784677
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
Number: NCT03824652
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
Number: NCT03824808
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): University of Missouri-Columbia
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1
Number: NCT03837353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NYU Langone Health|Leap Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Number: NCT03849469
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Xencor, Inc.|ICON Clinical Research
Sponsor Trial Information
Trial Location(s) and Contact(s) |
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer
Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
Number: NCT03939689
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy
Number: NCT03949517
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Andrei Iagaru|General Electric|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seagen Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s) |
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Safety and Targeting of Anti-hk2 Antibody in mCRPC
Number: NCT04116164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Tomopath Inc.|Invicro|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme Corp.|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
Number: NCT04122976
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase:
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy
Number: NCT04179864
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Epizyme, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Number: NCT04253262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Brown University|Rhode Island Hospital|The Miriam Hospital|Bayer|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy
Number: NCT04288336
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Number: NCT04288687
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Abramson Cancer Center of the University of Pennsylvania
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
Number: NCT04335682
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance Foundation Trials, LLC.|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Number: NCT04337580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
Number: NCT04349501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Diego
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Number: NCT04363164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|United States Department of Defense
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Number: NCT04382898
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioNTech SE
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Number: NCT04455750
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy
Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme Corp.|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Number: NCT04486755
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Number: NCT04514484
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Number: NCT04521686
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Eli Lilly and Company|Loxo Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Number: NCT04556617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Plexxikon
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Number: NCT04592237
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s) |
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
Number: NCT04597359
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
Number: NCT04645810
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Rochester
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Insulin Resistance Following ADT for Prostate CA
Number: NCT04658849
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): St. Louis University
Sponsor Trial Information
Trial Location(s) and Contact(s) |
ARX517 in Subjects With Advanced Solid Tumor
Number: NCT04662580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ambrx, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
Number: NCT04698564
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s) |
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Number: NCT04716725
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco|Conquer Cancer Foundation|Gateway for Cancer Research|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
Number: NCT04725903
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
Number: NCT04731844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Rochester
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Number: NCT04743934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew McDonald|University of Alabama at Birmingham
Sponsor Trial Information
Trial Location(s) and Contact(s) |
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Number: NCT04768868
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Impact Therapeutics, Inc.|Covance
Sponsor Trial Information
Trial Location(s) and Contact(s) |
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
Number: NCT04777071
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
Number: NCT04842890
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The New York Proton Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
Number: NCT04879940
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s) |
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
Number: NCT04927663
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Michael Evans|U.S. Army Medical Research Acquisition Activity|National Institute of Mental Health (NIMH)|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
Number: NCT04943536
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Alessa Therapeutics Inc.|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
Number: NCT04976257
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Ryan Kohlbrenner, MD|Radiological Society of North America|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
Number: NCT04984343
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Viewray Inc.|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease
Number: NCT05045066
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Number: NCT05050084
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of PRT2527 in Patients With Advanced Solid Tumors
Number: NCT05159518
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Prelude Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Number: NCT05160597
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Number: NCT05169970
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s) |
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Number: NCT05215574
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s) |